What we do
Anders has more than 15 years of experience as a biotech executive and investor. He is a co-founder of Orphazyme A/S where he served as CEO from 2009 … to 2019. In Orphazyme he led the formation of a late-development stage biopharmaceuticals company with a focus on rare and neurodegenerative diseases, as well as the IPO on NASDAQ in Copenhagen in 2017 raising 90 MUSD. Prior to Orphazyme, he was a Partner in a major Danish life science dedicated venture capital fund, BankInvest Biomedical Venture, where he also served as a Director in Boards including Santaris Pharma and F2G. Anders holds a M.Sc. in Human Biology and a Ph.D. in Medicine from the University of Copenhagen. +
Casper Tind Hansen
Casper has 15 years of expertise in pharma, biotech, and venture capital. He has taken on various roles in Marketing and Business Development… at Lundbeck and Nycomed, he was part of the investment team at Novo Ventures, and has been CEO of Pcovery, a Danish Discovery stage biotech company. Casper is the co-founder of Orphazyme and Embark Biotech. He holds a M.Sc in Human Biology from the University of Copenhagen.
Ian has over 15 years of experience in building companies, franchises, portfolios and products. He has had senior roles with increasing responsibility within R&D,… Business Development, and Marketing at Nycomed and Takeda; overseeing development of key assets in Alzheimer’s Disease, Schizophrenia and Depression. Ian holds a B.Sc. in Biochemistry from the University of Waterloo, and a M.Sc. in Biochemistry and MBA from the University of Ottawa.
Jakob Dynnes Hansen
More than 25 years of experience from biotech and financing. Previously, CFO of Evolva, a Swiss public biotech company, Nuevolution and Zealand Pharma, Senior member… of Corporate Finance Team at Unibank (now Nordea), Head of Market Research at Novo Nordisk. MSc (Econ.,University of Copenhagen), MBA (INSEAD)+
Non-executive Director in various European biotech companies (Synklino Aps. (DK), Neophore Ltd. (UK), Storm Ltd. (UK), Agomab Therapeutics (Belgium), and Synact Pharma AB (Sweden) …in addition to being an advisor to BiOrigin. Previously, he was the CEO of F-star in Cambridge, UK (2012-2018), where he built a successful biotech company, that initiated two clinical trials in oncology and generated more than €200M in non-dilutive revenue. Before, he was VP Research at ImClone Systems, New York (2010-2012) and Chief Scientific Officer and cofounder of Symphogen A/S, Denmark (2000-2009). After graduating in Medicine in Aarhus, Denmark (1992), Dr. Haurum received a D.Phil. in Immunology from University of Oxford, UK based on work done at the Institute of Molecular Medicine, John Radcliffe Hospital, Oxford. Subsequently, he took up positions as Associate Professor at the Danish Cancer Society and completed his medical training.+
Line Kromann Jørgensen
Line has more than 20 years of experience in financial management. She has a background as senior auditor at Deloitte followed by Finance Manager roles at Momondo A/S. …In addition to her main focus on accounting and reporting, Line is well founded in general tax and VAT matters. At BiOrigin, she supports client management with budgeting, reporting and other financial management. Line holds a M.Sc. in Business Economics and Auditing from the Copenhagen Business School.+
Dr. Fischer has 24 years experience from the biotech and pharmaceutical industry within product development and business development. He has experience from product… and business development in big pharma, founded and run several biotech companies, and served a business and product development consultant within the sector. He holds a D.Phil. from University of Oxford and has 6 years of laboratory experience within immunology and infectious diseases. He currently serves as the CEO of MinervaX ApS, Helion Biotech ApS, and Fischer BioConsult ApS.+
Board of Directors
Partner of Novo Seeds. Emmanuelle has more than 10 years of experience in venture capital investment. She sits on the board of directors of… several European biotech companies, including IO Biotech, Inthera, Corwave, Antag Therapeutics and Minervax. Prior to joining Novo Seeds, Emmanuelle was Partner Life Sciences at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. From 2007 until 2014, she was part of Omnes capital (formerly Crédit Agricole Private Equity) life sciences team with multiple portfolio companies leading to successful exits or IPOs. She was also in charge of the Seed Stage Investment Program and actively invested and sat on the board of directors of several companies in Belgium and The Netherlands.
Joined Novo Holdings in 2018 and is a Principal in the Novo Seeds team. Jeroen has a broad background comprising of life science consultancy, biotech and venture… capital. Previously, Jeroen worked at M Ventures, the corporate investment group of Merck, focusing on early-stage investments in US, EU and Israel. Through his work in consultancy, Jeroen raised 10+ EUR million in funding for biotech and translational academic research. Jeroen worked in biotech at Syntaxin Ltd (acquired by Ipsen) and through his scientific training published several articles on innate immunity. He holds a PhD in immunology from the University of Amsterdam and has been a visiting fellow at the La Jolla Institute for Allergy and Immunology and University of Iowa.+